Supplementary Materials

The PDF file includes:

• Material and Methods
• Fig. S1. Changes in T cell subsets in patients with RRMS on teriflunomide treatment.
• Fig. S2. Influence of teriflunomide on proliferation and cytokine production.
• Fig. S3. Impact of antigen affinities and DHODH interference on proliferation.
• Fig. S4. Metabolic assessment of T cells under teriflunomide treatment.
• Fig. S5. Influence of DHODH inhibition on T cell metabolism, on gene expression of OT-I and OT-III T cells, on T_H1 differentiation and proliferation, and on T_reg subpopulations in EAE.
• Fig. S6. Metabolism of T cells from patients with RRMS and HCs.
• Fig. S7. Comparison of freshly isolated versus frozen PBMCs from HCs regarding immune cell subset composition and metabolism.
• Fig. S8. Additional information supporting methodology.
• Table S1. Demographics and baseline disease characteristics TERIDYNAMIC trial.
• Table S2. Differentially regulated genes depicted in Fig. 5I.
• Table S3. Demographics and baseline disease characteristics of HCs and treatment-naïve patients analyzed for TCR repertoire changes.
• Table S4. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment analyzed for TCR repertoire changes.
• Table S5. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment analyzed for immune cell phenotyping.
• Table S6. Demographics and baseline disease characteristics of patients before and during teriflunomide treatment for at least 6 months analyzed for suppressive capacity of T_regs.
• Table S7. Demographics and baseline disease characteristics of patients before and during teriflunomide treatment for at least 6 months analyzed for cytokine expression of T_regs.
• Table S8. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment for at least 6 months analyzed for myelin-specific T cell frequencies.
• Table S9. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment for at least 6 months analyzed for metabolic activity.
• Table S10. Demographics and baseline disease characteristics of treatment-naïve patients before and during treatment with DMF, IFN-β, or GLAT analyzed for TCR repertoire changes.
• Table S11. Demographics and baseline disease characteristics of HCs and treatment-naïve patients analyzed for metabolic activity.
• Table S12. Demographics and baseline disease characteristics of HCs and patients analyzed for metabolic activity after 72 hours of in vitro stimulation.
• Table S13. Demographics of HCs analyzed for immune cell phenotyping of freshly isolated versus frozen PBMCs.
• Table S14. Demographics of HCs analyzed for metabolic differences of T cells isolated from fresh blood or frozen PBMCs.
• References (36–38)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

• Data file S1 (Microsoft Excel format). Primary data.